title: High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: a phase II study. EORTC Genito-Urinary Tract Cancer Co-operative Group. EORTC Early Clinical Trials Group.
abstract: Eighteen patients with progressive disseminated, platinum-resistant germ cell tumors were treated with epirubicin 135 mg/m2, every 3 weeks. One patient had stable disease, 17 developed progression. Myelosuppression was dose-limiting. One patient died of neutropenic septicemia. High-dose epirubicin is not active against platinum-resistant germ cell cancer.
authors.affiliation: Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Stoter
authors.forename: A
authors.initials: A
authors.lastname: Akdas
authors.forename: S D
authors.initials: SD
authors.lastname: Fosså
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
authors.forename: C J
authors.initials: CJ
authors.lastname: van Groeningen
authors.forename: J
authors.initials: J
authors.lastname: Renard
authors.forename: M
authors.initials: M
authors.lastname: van Glabbeke
mesh_terms: D000293:Adolescent; D000328:Adult; D004341:Drug Evaluation; D015251:Epirubicin / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*
chemical_list: D015251:Epirubicin